Spago Nanomedical's vision is to engage in competitive and successful development of products for increased survival and quality of life for patients and thereby create long-term profitability for the company and its owners.
More Accurate Diagnosis and Treatments
The company’s operations are focused on the development of SpagoPix, a cancer-selective contrast agent for magnetic resonance imaging (MRI), and Tumorad® for radiopharmaceutical therapy of cancer. Both projects are built on a patented platform of polymeric materials with unique properties that enable more accurate diagnosis and treatment of solid tumors. SpagoPix and Tumorad® utilize the scientifically well-established EPR (Enhanced Permeability and Retention)-effect, which means that particles of a certain size will accumulate selectively in cancer tissue.
The SpagoPix project aims to launch a ground-breaking gadolinium-free MRI contrast agent for visualization of tumors and metastases. Unlike the conventional low molecular-weight MRI contrast agents, which enhance healthy tissue as well as tumor tissue, and therefore results in a relatively high proportion of false positive findings, Spago Nanomedical’s proprietary contrast agent is designed to selectively accumulate in tumor tissue. This improves the precision of MRI scans for suspected cancers. With better cancer diagnostics, the chances of successful and cost-efficient treatment of cancer patients improve. The Tumorad® project aims to develop a novel therapeutic radiopharmaceutical targeting solid tumors based on nanoparticles loaded with radioactive isotopes. The design of Tumorad® makes tumor selectivity possible even in the case of small, difficult-to-reach and aggressive tumors, which enables efficient radiation treatment of the cancer while minimizing the risk of adverse effects.
Spago Nanomedical´s share is listed on Nasdaq First North Growth Market in Stockholm (ticker: SPAGO).